FDA approves Unichem’s generic Dyazide

WASHINGTON The Food and Drug Administration has approved Unichem Laboratories’ hydrochlorothiazide tablets.

The tablets, available in 25 mg and 50 mg strengths, are used to treat edema, or fluid retention resulting from congestive heart failure, as well as kidney disorders and cirrhosis of the liver. The FDA also approved Unichem’s formulations plant in Ghaziabad, India.

The new drug is a generic version of GlaxoSmithKline’s Dyazide.